ANI eyes more deals to follow WellSpring
Executive Summary
ANI Pharmaceuticals is looking for further deals to accompany the US firm’s organic growth, according to president and chief executive Arthur Przybyl. In August, ANI acquired for US$18 million Canada-based WellSpring Pharma Services, in a bid to expand its contract manufacturing and development business, and to increase the US firm’s capacity to re-commercialise its pipeline of ANDAs that require a technology transfer from its local Baudette facility in Minnesota (Generics bulletin, 31 August 2018, page 14).
You may also be interested in...
Finance Watch: Recent Offerings Show Some Companies Were Ready For The Government Shutdown
Public Company Edition: The usual mid-January surge in public offerings hasn't happened this year, since the SEC can't process new filings, but Alnylam, Acceleron and others apparently were prepared for a lengthy shutdown. Also, ARM reports cell and gene therapy financing data.
Cardio Catch-Up: Boston Scientific's Farapulse PFA Shows Short Learning Curve In European Registry
Medtech Insight’s Cardiovascular Catch-Up highlights recent news on cardiovascular tech innovations that you may have missed. This edition recaps the presentation of results from EU PORIA, a European registry atrial fibrillation patients treated with Boston Scientific's Farapulse pulsed field ablation system.